ATE378353T1 - Neurotrophe faktoren - Google Patents

Neurotrophe faktoren

Info

Publication number
ATE378353T1
ATE378353T1 AT02706759T AT02706759T ATE378353T1 AT E378353 T1 ATE378353 T1 AT E378353T1 AT 02706759 T AT02706759 T AT 02706759T AT 02706759 T AT02706759 T AT 02706759T AT E378353 T1 ATE378353 T1 AT E378353T1
Authority
AT
Austria
Prior art keywords
neurotrophic factors
neublastin
polypeptides
methods
antibodies
Prior art date
Application number
AT02706759T
Other languages
English (en)
Inventor
Dinah Sah
Teit Johansen
Anthony Rossomando
Original Assignee
Biogen Idec Inc
Nsgene As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Nsgene As filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of ATE378353T1 publication Critical patent/ATE378353T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
AT02706759T 2001-03-12 2002-03-12 Neurotrophe faktoren ATE378353T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/804,615 US20020055467A1 (en) 1998-07-06 2001-03-12 Novel neurotrophic factors

Publications (1)

Publication Number Publication Date
ATE378353T1 true ATE378353T1 (de) 2007-11-15

Family

ID=25189406

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02706759T ATE378353T1 (de) 2001-03-12 2002-03-12 Neurotrophe faktoren
AT07120461T ATE509103T1 (de) 2001-03-12 2002-03-12 Neurotrophe faktoren

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT07120461T ATE509103T1 (de) 2001-03-12 2002-03-12 Neurotrophe faktoren

Country Status (16)

Country Link
US (1) US20020055467A1 (de)
EP (2) EP1930439B1 (de)
JP (2) JP3738008B2 (de)
CN (1) CN1268744C (de)
AT (2) ATE378353T1 (de)
AU (1) AU2002240943B2 (de)
CA (1) CA2440767C (de)
CY (1) CY1111750T1 (de)
DE (1) DE60223511T2 (de)
DK (2) DK1930439T3 (de)
ES (2) ES2366610T3 (de)
HK (1) HK1120556A1 (de)
NZ (1) NZ528790A (de)
PT (2) PT1373503E (de)
SI (2) SI1930439T1 (de)
WO (1) WO2002072826A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
CA2333910C (en) * 1998-07-14 2016-11-15 Janssen Pharmaceutica N.V. Neurotrophic growth factor
IL156559A0 (en) * 2000-12-22 2004-01-04 Genentech Inc New use of artemin, a member of the gdnf ligand family
US7442370B2 (en) * 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
ATE526982T1 (de) * 2001-03-28 2011-10-15 Biogen Idec Inc Verwendung von neublastin-polypeptide zur behandlung von neuropathischen schmerzen
EP1463530A4 (de) * 2001-12-19 2006-09-06 Lijun Wang Adeno-assoziierte virusvermittelte abgabe von gdnf an skelettmuskeln
JP4571776B2 (ja) * 2002-11-05 2010-10-27 Ｊｘ日鉱日石エネルギー株式会社 潤滑油組成物
JP4742025B2 (ja) * 2003-01-31 2011-08-10 バイオジェン・アイデック・エムエイ・インコーポレイテッド 変異ニューブラスチンのポリマー結合体
EP2322205A1 (de) * 2003-04-18 2011-05-18 Biogen Idec MA Inc. Polymerkonjugiertes glycosiliertes Neublastin
WO2004108760A2 (en) * 2003-06-10 2004-12-16 Nsgene A/S Improved secretion of neublastin
US7598059B2 (en) * 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
NZ547185A (en) 2003-10-20 2009-03-31 Nsgene As In vivo gene therapy of parkinson's disease
WO2006023782A2 (en) 2004-08-19 2006-03-02 Biogen Ideca Ma Inc. Refolding transforming growth factor beta family proteins
MX2007002029A (es) * 2004-08-19 2007-03-28 Biogen Idec Inc Variantes de neublastina.
WO2007042040A2 (en) * 2005-10-11 2007-04-19 Ns Gene A/S TREATMENT OF RETINOPATHIES USING GFRα3 AGONISTS
TWI501774B (zh) * 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
ES2450065T3 (es) * 2006-03-01 2014-03-21 Biogen Idec Ma Inc. Composiciones y métodos para la administración de proteínas de la familia de ligandos del GDNF
TWI445544B (zh) * 2007-05-01 2014-07-21 Biogen Idec Inc 增進血管形成之組合物及方法
WO2009020964A2 (en) * 2007-08-08 2009-02-12 Biogen Idec Ma Inc. Anti-neublastin antibodies and uses thereof
WO2009045813A1 (en) * 2007-10-01 2009-04-09 Vgx Pharmaceuticals, Inc. Materials and methods for the delivery of biomolecules to cells of an organ
KR101886029B1 (ko) * 2010-10-01 2018-08-07 호바 세라퓨틱스 에이피에스 무해자극통증, 통각과민증, 자발통증 및 헛통증의 치료를 위한 메테오린의 용도
US20190381138A1 (en) * 2018-05-17 2019-12-19 Helixmith Co., Ltd. Treatment of neuropathic pain associated with chemotherapy-induced peripheral neuropathy
KR20240008844A (ko) 2021-05-18 2024-01-19 가부시키가이샤 엘티티 바이오파마 항암제의 투여에 수반되는 장애를 치료 또는 예방하기 위한 의약 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
WO1997044356A2 (en) 1996-05-08 1997-11-27 Biogen, Inc. RET LIGAND (RetL) FOR STIMULATING NEURAL AND RENAL GROWTH
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
US20020002269A1 (en) * 1998-09-29 2002-01-03 Jeffrey D. Milbrandt Artemin, a neurotrophic factor
EP1137774A2 (de) * 1998-12-09 2001-10-04 Amgen Inc. Grnf4, ein gdnf-ähnlicher neurotropher faktor
DK1185648T3 (da) * 1999-06-02 2007-07-30 Genentech Inc Fremgangsmåder og sammensætninger til inhibition af neoplastisk cellevækst

Also Published As

Publication number Publication date
JP2004531242A (ja) 2004-10-14
PT1930439E (pt) 2011-07-25
DE60223511T2 (de) 2008-10-23
EP1373503A2 (de) 2004-01-02
US20020055467A1 (en) 2002-05-09
ES2366610T3 (es) 2011-10-21
CA2440767A1 (en) 2002-09-19
CN1268744C (zh) 2006-08-09
CN1509333A (zh) 2004-06-30
EP1930439B1 (de) 2011-05-11
JP2005198656A (ja) 2005-07-28
CA2440767C (en) 2012-05-29
CY1111750T1 (el) 2015-10-07
AU2002240943B2 (en) 2007-05-10
HK1120556A1 (en) 2009-04-03
JP3738008B2 (ja) 2006-01-25
SI1373503T1 (sl) 2008-04-30
SI1930439T1 (sl) 2011-09-30
WO2002072826A2 (en) 2002-09-19
WO2002072826A3 (en) 2003-04-10
ES2296899T3 (es) 2008-05-01
PT1373503E (pt) 2008-02-26
DK1930439T3 (da) 2011-08-29
AU2002240943A2 (en) 2002-09-24
EP1373503B1 (de) 2007-11-14
DE60223511D1 (de) 2007-12-27
DK1373503T3 (da) 2008-03-25
ATE509103T1 (de) 2011-05-15
EP1930439A1 (de) 2008-06-11
NZ528790A (en) 2004-06-25

Similar Documents

Publication Publication Date Title
CY1111750T1 (el) Νευροτροφικοι παραγοντες
ATE522609T1 (de) Neurotrophe faktoren
DK1434791T3 (da) Specifikke bindingsmidler til human angiopoietin-2
ATE411082T1 (de) Neue verwendung von kurzkettigen carbonsäuren
PT1015585E (pt) Homologos de ligandos de tie
BR0012759A (pt) Neurotoxinas recombinantes ativáveis
EA200400510A1 (ru) Агенты, специфически связывающие ангиопоэтин-2
NO20054836L (no) Nogo-reseptorbindingsprotein
WO2007045019A3 (en) Polyoleosins
ATE309356T1 (de) Konstruierte fluoreszenzproteine mit langen wellenlängen
ATE550345T1 (de) Sfrp, mit sfrp-interagierende peptidmotive sowie verwendungsverfahren
EA200400392A1 (ru) Связывающий каспазу-8 белок, его получение и применение
EA200100110A1 (ru) Нейротрофические факторы
ATE325873T1 (de) Androgenrezeptor-komplex assoziiertes protein
WO2001021794A3 (en) Smad associating polypeptides

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1373503

Country of ref document: EP